The FDA issued national priority vouchers to three companies studying psychedelic drugs for serious mental health conditions, marking accelerated action on treatments following an executive order. The vouchers allow expedited FDA review for psilocybin treatments for treatment-resistant depression and major depressive disorder, as well as methylone for post-traumatic stress disorder.
FDA Support and Standards
“There is a growing recognition of the potential of psychedelic medications to address multiple different psychiatric conditions that are notoriously difficult to treat,” said Tracy Beth Hoeg, M.D., Ph.D., Acting Director of the FDA’s Center for Drug Evaluation and Research. The FDA’s decision allows studies to proceed but does not mean the drugs have been approved or found to be safe or effective. The agency will continue to review data as it becomes available and support efforts to develop new treatments for alcohol use disorder and other mental health conditions.
Government Commitment
Health and Human Services Secretary Robert F. Kennedy Jr. stated: “We are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans.” The FDA will prioritize therapies with Breakthrough Therapy designation, where early evidence shows meaningful improvement over existing options for serious mental illness. The agency is also allowing an early-phase clinical study of noribogaine hydrochloride as a possible treatment for substance use disorder and other conditions to proceed.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/04/g52046082/fda-accelerates-action-on-treatments-for-serious-mental-illness-following-executive-order